Cameron Beene, PharmD

Medical Science Liaison; GI Division; Passionate about IBD; Crohn’s and Ulcerative Colitis. Major interest: most impactful IBD studies. Tweets are my own

[GutMicrobiota Health @GMFHx]

Crohn's disease gut biology may shift from active to remission

@ShomronH et al. found that perturbations in dietary, ileal, microbial, and metabolic signatures persist during CD remission despite effective immune-targeted treatments

@AGA_Gastro  

https://t.co/cWgQscvuOV

[Jana G Hashash, MD, MSc @JHashashMD]

MUST READ📖
Joint @RomeFoundation & @IOIBD1 RAND/UCLA Recommendations for #Evaluation & #Managmt of #IBD with #IBS-like Symptoms @AGA_Gastro

https://t.co/TAfqa31eTZ

📝Nomenclature: IBD with IBS-like symptoms

Evaluation🩺 🧫

Therapies
🥗Diet
💊Drugs💉
🧠Brain gut behavioral tx

[ACG @AmCollegeGastro]

Save the date for a special IBD Circle ACG Virtual Grand Rounds!

Bringing Latest ACG Guidelines to Life: Practical, Case-Based Insights for IBD Care
Wednesday, August 20 at 8:00pm ET

Register: https://t.co/yRsHiWYaXL

@IBD_Afzali @IBDMD @SunandaKaneMD @JPAchkarMD

[Tauseef Ali MD, FACG AGAF FACP @ibdtweets]

🎯 Extending the Half-Life of mAbs: Why It Matters in IBD

In Crohn’s disease and ulcerative colitis, therapeutic monoclonal antibodies often require frequent dosing—which can burden patients and strain healthcare systems.

🧬 Enter Fc engineering: By tweaking the Fc region of antibodies, we can achieve:
✅ Longer half-life
✅ Reduced dosing frequency
✅ Better mucosal drug retention
✅ Lower immunogenicity risk

This fun cartoon breaks down 6 key Fc engineering strategies—including YTE, LS, LALA (Remember Risankizumab! ) , and catch-and-release—with direct applications for managing IBD.

Imagine future mAbs needing only 1 injection every 4-6 months or even longer, with less immune activation and greater mucosal healing. We're not far off!

[Beatriz Gros @Bealoquebea]

📣What impacts sustainability in IBD care the most?
We are looking to hear your opinion!

⬇️⬇️⬇️⬇️
https://t.co/IsNO2cO2i7

@olganardone @tommasoparigi

[Charlie Lees @charlie_lees]

We have an amazing opportunity for someone to do a 3 year IBD focused data science PhD in Edinburgh as part of a fully funded OPEN-IBD fellowship.

It’s a fantastic department, in a beautiful city, and the clinical commitment will be ~20% to recruit patients to OPEN IBD with the remaining time dedicated to doing the PhD.

Full-time salary & PhD fees covered.

Reach out to @JonnyBlackwell or me for an informal chat if interested.

@EdinUni_IGC @EdinburghUni @NHS_Lothian @OpenIBD

https://t.co/Jc91N2ckGr

[Nicholas Fabiano, MD @NTFabiano]

The optimal amount of exercise to improve cognitive function.

🧵1/10

[Gastroenterology @AGA_Gastro]

🔔 From GHA ⬇️Check it out!

📣 Novel stool RNA test discriminates Crohn's disease activity with 81% accuracy and stratifies severity with 92% accuracy

👨‍🔬 @GeneoscopyCo @P_DeepakIBDMD @CiorbaGI @EricaBarnell

🔗 https://t.co/Ntkkv2Lgib

[Adam Grant @AdamMGrant]

What leads us to ignore experts isn't their knowledge. It's their arrogance.

Evidence: Scientists are more credible when they admit what they don't know, acknowledge what they got wrong, and update their views.

Trust is earned by expressing humility, not by asserting authority.

[Beatriz Gros @Bealoquebea]

Thanks @NabilQuraishi that very kindly highlighted that I missed risankizumab dose in UC
🙏🏻🙏🏻🙏🏻🙏🏻

[John Damianos, M.D. @john_damianosMD]

Living clinical guideline on ulcerative colitis medical management

#MedTwitter #GITwitter #IBD

https://t.co/uszEcvjorf

[Nisha Loganantharaj @nloganmd]

📣 Fellows to mid-career attendings check out this helpful IBD-REACH webinar 👩🏾‍💻
💎Negotiate your upcoming GI/IBD job
🦻🏽all about career transitions

Sign up today for this FREE webinar!!

[Ildiko ☕️ @IldikoMe]

Good paper.

Claudin-2: A marker for a better evaluation of histological mucosal healing in IBD
https://t.co/ROOk3xhv86

[Robert Dudkowiak MD, PhD @drRobinDud]

Real-World 🇫🇷🇩🇪🇮🇹🇪🇸🇬🇧🇺🇸 study
abt how BIG and challenging📍problem
is #BowelUrgency in #colitis & #crohns

Despite conventional or targeted therapy
17-26% #UC & 13-17% #CD pts has🔥BowelU

#IBDpatients with BU has⬆️clinical & health-related QoL burden

https://t.co/1bRcI8cXwX

[JPGN @JPGNonline]

Implementing a standardized protocol for steroid weaning in pediatric #IBD patients led to a significant reduction in #steroid use without increasing flares or hospitalizations. #Pediatrics #QI

https://t.co/61ZjK2iYWe

[Journal of Crohn's and Colitis @JCC_IBD]

Fecal #calprotectin levels incrementally increase hand-in-hand with extension of inflammation from proximal to distal parts of the small bowel. @ShomronH @OffirU

https://t.co/dVJMHWELdH

[PREDICT IBD @PREDICTIBD]

SIGNS OF INFLAMMATORY CHANGES PRESENT AT BIRTH IN VEO-IBD PATIENTS 👦🏼👧🏾🔬🧫🧪

In this unique study, using neonatal blood samples from 464 individuals who later developed IBD, we observed decreased levels of IL-4 and increased levels of IL-17A.

Link ➡️ https://t.co/Y50a1h7e5O

[Scott Isaacs @scottisaacsmd]

The emerging role of GLP-1 medications for the treatment of #MASH.
https://t.co/UCVoDB9YpJ

[Uma Mahadevan @UmaMahadevanIBD]

Live rotavirus vaccine can be given to infants exposed to anti-TNF in utero. Will be in the Global Consensus guidelines. Great work by @SeowCynthia and colleagues!
LIVE ROTAVIRUS VACCINATION APPEARS LOW-RISK IN INFANTS BORN TO MOTHERS... https://t.co/0Z7wRSh4JB